Vestal Point Capital’s Aprea Therapeutics APRE Stock Holding History
Bought
Maintained
Sold
Other funds holding APRE
ACM
Vestal Point Capital's APRE Position: Q3 2026 in Review
Vestal Point Capital held its Aprea Therapeutics (APRE) position steady in Q3 2026 at 350,000 shares worth $262K. The position accounts for 0.01% of the portfolio, ranked #63.
Vestal Point Capital first reported a position in APRE in Q1 2026 and has held it in 3 quarters since. The position peaked at $281K in Q2 2026. 28 funds tracked by Wall St. Rank hold APRE as of Q3 2026.
- Vestal Point Capital held 350,000 shares of Aprea Therapeutics worth $262K as of Q3 2026.
- Vestal Point Capital left its Aprea Therapeutics share count unchanged in Q3 2026.
- Aprea Therapeutics made up 0.01% of Vestal Point Capital's portfolio in Q3 2026, its #63 holding.
- Vestal Point Capital first reported a position in Aprea Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vestal Point Capital's Aprea Therapeutics position peaked at $281K in Q2 2026.
- 28 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q3 2026.
Based on Vestal Point Capital's 13F filing for Q3 2026, filed 16 Nov 2026.